Amelia Jackson on October 29, 2025 7:42 am Exploration results look promising, but permitting will be the key risk. Reply
Emma E. Jackson on October 29, 2025 7:43 am Silver leverage is strong here; beta cuts both ways though. Reply
Emma N. Williams on October 29, 2025 7:43 am Interesting update on The MP5SD: The SMG That’s Seen More Brains Than a Brain Surgeon. Curious how the grades will trend next quarter. Reply
Michael Hernandez on October 29, 2025 7:43 am I like the balance sheet here—less leverage than peers. Reply
Mary G. Davis on October 29, 2025 7:44 am Nice to see insider buying—usually a good signal in this space. Reply
Robert D. Thompson on October 29, 2025 7:48 am Exploration results look promising, but permitting will be the key risk. Reply
Ava W. Thompson on October 29, 2025 7:49 am Silver leverage is strong here; beta cuts both ways though. Reply
John Smith on October 29, 2025 7:50 am Interesting update on The MP5SD: The SMG That’s Seen More Brains Than a Brain Surgeon. Curious how the grades will trend next quarter. Reply
William Lee on October 29, 2025 7:51 am The cost guidance is better than expected. If they deliver, the stock could rerate. Reply
Ava Hernandez on October 29, 2025 7:55 am Interesting update on The MP5SD: The SMG That’s Seen More Brains Than a Brain Surgeon. Curious how the grades will trend next quarter. Reply
20 Comments
Exploration results look promising, but permitting will be the key risk.
Silver leverage is strong here; beta cuts both ways though.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
Interesting update on The MP5SD: The SMG That’s Seen More Brains Than a Brain Surgeon. Curious how the grades will trend next quarter.
I like the balance sheet here—less leverage than peers.
Good point. Watching costs and grades closely.
Nice to see insider buying—usually a good signal in this space.
Exploration results look promising, but permitting will be the key risk.
Good point. Watching costs and grades closely.
Silver leverage is strong here; beta cuts both ways though.
Interesting update on The MP5SD: The SMG That’s Seen More Brains Than a Brain Surgeon. Curious how the grades will trend next quarter.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
The cost guidance is better than expected. If they deliver, the stock could rerate.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
Interesting update on The MP5SD: The SMG That’s Seen More Brains Than a Brain Surgeon. Curious how the grades will trend next quarter.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.